Device Update
Temple: A New Wearable Exploring Brain Blood-Flow Patterns
Wearable health technology is gradually moving beyond conventional fitness measurements such as heart rate, step count and sleep duration to explore more complex aspects of human physiology. Temple, a new wearable device developed by Zomato founder Deepinder Goyal, aims to monitor changes in blood-flow signals towards the brain. Unlike conventional smartwatches and fitness bands, Temple is designed to be worn on either side of the forehead, near the temples. It uses light-based sensors to detect variations in blood-flow signals, a measurement its developers call BrainFlow. The device aims to capture how these signals change under different everyday conditions, including physical exercise, rest and mental stress. By monitoring these variations, it intends to provide users with a better understanding of their physiological responses to different activities and levels of exertion. This approach introduces a relatively new dimension to consumer wearables by focusing on brain-related blood-flow patterns rather than relying exclusively on traditional fitness indicators.
One of the device's additional features is an Entropy score, designed to offer an overall indication of physiological strain. It considers factors such as physical activity, rest, mental stress and caffeine intake to help users observe how different lifestyle factors may influence their body's responses. For example, users may be able to compare their readings during periods of exercise, recovery or mental stress and identify patterns over time. However, it is important to understand the distinction between monitoring physiological signals and diagnosing a medical condition. Temple cannot diagnose stroke, brain tumours or other neurological diseases. It cannot independently determine the cause of symptoms such as headaches, dizziness, fatigue or difficulty concentrating, nor can it replace clinical assessments, neurological examinations or medical imaging. Changes in BrainFlow readings should not automatically be interpreted as evidence of impaired brain function or disease. Blood-flow signals represent only one component of the complex processes involved in brain health.
The first batch of Temple devices is scheduled to open for pre-orders on November 1, 2026, with each device reportedly made to order and deliveries expected within three months. The device reflects the growing interest in wearable technologies that aim to provide continuous insights into physiological functions beyond routine health tracking. If validated, such measurements could potentially help users understand personal patterns associated with activity, rest and stress. Nevertheless, the usefulness of Temple will depend on the accuracy and consistency of its measurements, independent scientific validation and evidence that the information it provides has meaningful real-world or clinical relevance. Further research will be needed to establish how BrainFlow and the Entropy score should be interpreted and whether they can offer reliable insights into health. Until then, Temple is best viewed as an exploratory health-monitoring tool rather than a device for assessing or diagnosing brain disorders. Its readings should complement general health awareness and never replace professional medical evaluation.
Drug Update
A New Research Initiative Brings Hope for a Preventive Hepatitis C Vaccine
Hepatitis C virus (HCV) remains a major global health challenge, with approximately 50 million people worldwide living with chronic infection. Although modern antiviral medicines can cure most treated patients, the absence of an effective preventive vaccine continues to be a major barrier to controlling transmission and reducing the long-term burden of the disease. Chronic HCV infection can lead to serious complications, including liver cirrhosis and liver cancer. Developing a vaccine has been particularly challenging because the virus mutates rapidly, producing numerous genetic variants that can evade the immune system. A successful vaccine must therefore stimulate immune protection against different HCV variants by targeting relatively stable regions of the virus.
In a significant step towards this goal, the National Institutes of Health (NIH) has awarded US$16.4 million over five years to establish the Cooperative Center for Rational HCV Vaccine Design & Evaluation. Led by researchers at Scripps Research, the initiative brings together experts from the National Institute of Diabetes and Digestive and Kidney Diseases, the University of Pennsylvania and the Oregon National Primate Research Center. The research will focus on two major areas: understanding how antibodies recognize specific structures on the virus and developing vaccine candidates capable of generating strong antibody and T-cell responses. Advanced technologies, including X-ray crystallography, cryo-electron microscopy and cryo-electron tomography, will help researchers examine viral structures and their interactions with antibodies. Different vaccine prototypes will then be evaluated using standardized testing methods to identify candidates that can provide broader immune protection.
The initiative also aims to establish a publicly accessible database of HCV immune responses and advance the most promising vaccine candidates towards Good Manufacturing Practice (GMP) development, an important stage before clinical trials. Although this funding represents an important research milestone, it does not mean that a vaccine is ready for human use. The candidates will need to undergo further laboratory and preclinical evaluation before clinical testing can begin. If successful, this collaborative effort could help overcome one of the biggest obstacles in hepatitis C prevention and contribute to the long-term goal of reducing transmission and potentially eliminating the disease.